Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C15H12I3NO4 |
Molecular Weight | 650.9735 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](CC1=CC(I)=C(OC2=CC=C(O)C(I)=C2)C(I)=C1)C(O)=O
InChI
InChIKey=AUYYCJSJGJYCDS-LBPRGKRZSA-N
InChI=1S/C15H12I3NO4/c16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22/h1-4,6,12,20H,5,19H2,(H,21,22)/t12-/m0/s1
Molecular Formula | C15H12I3NO4 |
Molecular Weight | 650.9735 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/6617571http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10379s47lbl.pdfCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68014284
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6617571http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10379s47lbl.pdf
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68014284
Liothyronine (CYTOMEL®) is a T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than its prohormone thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3. The mechanisms by which thyroid hormones exert their physiologic action are not well understood. These hormones enhance oxygen consumption by most tissues of the body, increase the basal metabolic rate and the metabolism of carbohydrates, lipids, and proteins. Thus, they exert a profound influence on every organ system in the body and are of particular importance in the development of the central nervous system. Thyroid hormone drugs are indicated: as the replacement or supplemental therapy in patients with hypothyroidism of any etiology; as pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters; as diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1860 |
0.1 nM [Kd] | ||
Target ID: CHEMBL1947 |
0.1 nM [Kd] | ||
Target ID: CHEMBL1860 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12109914 |
0.1 nM [Kd] | ||
Target ID: CHEMBL1947 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12109914 |
0.1 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CYTOMEL Approved UseThyroid hormone drugs are indicated:
1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism.
2. As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s) and multinodular goiter.
3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. Launch Date-4.3079041E11 |
|||
Primary | CYTOMEL Approved UseThyroid hormone drugs are indicated:
1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism.
2. As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s) and multinodular goiter.
3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. Launch Date-4.3079041E11 |
|||
Diagnostic | CYTOMEL Approved UseThyroid hormone drugs are indicated:
1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism.
2. As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s) and multinodular goiter.
3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. Launch Date-4.3079041E11 |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
346 ng/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379 |
50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
LIOTHYRONINE SODIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
342 ng/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379 |
50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
LIOTHYRONINE SODIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
404 ng/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379 |
50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
LIOTHYRONINE SODIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4370 ng × h/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379 |
50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
LIOTHYRONINE SODIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4740 ng × h/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379 |
50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
LIOTHYRONINE SODIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4926 ng × h/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379 |
50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
LIOTHYRONINE SODIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
12929 ng × h/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379 |
50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
LIOTHYRONINE SODIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
13938 ng × h/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379 |
50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
LIOTHYRONINE SODIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
22.04 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379 |
50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
LIOTHYRONINE SODIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
10794.4 ug 2 times / day multiple, oral Overdose Dose: 10794.4 ug, 2 times / day Route: oral Route: multiple Dose: 10794.4 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 20 n = 1 Health Status: unhealthy Condition: Fatigue Age Group: 20 Sex: M Population Size: 1 Sources: Page: p.2 |
Disc. AE: Anxiety, Palpitations... AEs leading to discontinuation/dose reduction: Anxiety (severe) Sources: Page: p.2Palpitations Agitation Shortness of breath Irritability Tachycardia Tremor |
15000 ug 2 times / day multiple, oral Overdose Dose: 15000 ug, 2 times / day Route: oral Route: multiple Dose: 15000 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 30 n = 1 Health Status: unhealthy Condition: Hypothyroidism Age Group: 30 Sex: F Population Size: 1 Sources: Page: p.2 |
Disc. AE: Nausea, Vomiting... AEs leading to discontinuation/dose reduction: Nausea Sources: Page: p.2Vomiting Abdominal pain Headache (severe) Confusion Disorientation Diplopia |
50 ug 2 times / day multiple, oral Highest studied dose Dose: 50 ug, 2 times / day Route: oral Route: multiple Dose: 50 ug, 2 times / day Sources: Page: p.3 |
unhealthy, 39 ± 6.2 n = 2 Health Status: unhealthy Condition: Multiple sclerosis Age Group: 39 ± 6.2 Sex: M+F Population Size: 2 Sources: Page: p.3 |
DLT: Anxiety, Tachycardia... Dose limiting toxicities: Anxiety (50%) Sources: Page: p.3Tachycardia (50%) Loose stools (100%) |
37.5 ug 2 times / day multiple, oral MTD Dose: 37.5 ug, 2 times / day Route: oral Route: multiple Dose: 37.5 ug, 2 times / day Sources: Page: p.3 |
unhealthy, 39 ± 6.2 n = 4 Health Status: unhealthy Condition: Multiple sclerosis Age Group: 39 ± 6.2 Sex: M+F Population Size: 4 Sources: Page: p.3 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Agitation | Disc. AE | 10794.4 ug 2 times / day multiple, oral Overdose Dose: 10794.4 ug, 2 times / day Route: oral Route: multiple Dose: 10794.4 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 20 n = 1 Health Status: unhealthy Condition: Fatigue Age Group: 20 Sex: M Population Size: 1 Sources: Page: p.2 |
Irritability | Disc. AE | 10794.4 ug 2 times / day multiple, oral Overdose Dose: 10794.4 ug, 2 times / day Route: oral Route: multiple Dose: 10794.4 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 20 n = 1 Health Status: unhealthy Condition: Fatigue Age Group: 20 Sex: M Population Size: 1 Sources: Page: p.2 |
Palpitations | Disc. AE | 10794.4 ug 2 times / day multiple, oral Overdose Dose: 10794.4 ug, 2 times / day Route: oral Route: multiple Dose: 10794.4 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 20 n = 1 Health Status: unhealthy Condition: Fatigue Age Group: 20 Sex: M Population Size: 1 Sources: Page: p.2 |
Shortness of breath | Disc. AE | 10794.4 ug 2 times / day multiple, oral Overdose Dose: 10794.4 ug, 2 times / day Route: oral Route: multiple Dose: 10794.4 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 20 n = 1 Health Status: unhealthy Condition: Fatigue Age Group: 20 Sex: M Population Size: 1 Sources: Page: p.2 |
Tachycardia | Disc. AE | 10794.4 ug 2 times / day multiple, oral Overdose Dose: 10794.4 ug, 2 times / day Route: oral Route: multiple Dose: 10794.4 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 20 n = 1 Health Status: unhealthy Condition: Fatigue Age Group: 20 Sex: M Population Size: 1 Sources: Page: p.2 |
Tremor | Disc. AE | 10794.4 ug 2 times / day multiple, oral Overdose Dose: 10794.4 ug, 2 times / day Route: oral Route: multiple Dose: 10794.4 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 20 n = 1 Health Status: unhealthy Condition: Fatigue Age Group: 20 Sex: M Population Size: 1 Sources: Page: p.2 |
Anxiety | severe Disc. AE |
10794.4 ug 2 times / day multiple, oral Overdose Dose: 10794.4 ug, 2 times / day Route: oral Route: multiple Dose: 10794.4 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 20 n = 1 Health Status: unhealthy Condition: Fatigue Age Group: 20 Sex: M Population Size: 1 Sources: Page: p.2 |
Abdominal pain | Disc. AE | 15000 ug 2 times / day multiple, oral Overdose Dose: 15000 ug, 2 times / day Route: oral Route: multiple Dose: 15000 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 30 n = 1 Health Status: unhealthy Condition: Hypothyroidism Age Group: 30 Sex: F Population Size: 1 Sources: Page: p.2 |
Confusion | Disc. AE | 15000 ug 2 times / day multiple, oral Overdose Dose: 15000 ug, 2 times / day Route: oral Route: multiple Dose: 15000 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 30 n = 1 Health Status: unhealthy Condition: Hypothyroidism Age Group: 30 Sex: F Population Size: 1 Sources: Page: p.2 |
Diplopia | Disc. AE | 15000 ug 2 times / day multiple, oral Overdose Dose: 15000 ug, 2 times / day Route: oral Route: multiple Dose: 15000 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 30 n = 1 Health Status: unhealthy Condition: Hypothyroidism Age Group: 30 Sex: F Population Size: 1 Sources: Page: p.2 |
Disorientation | Disc. AE | 15000 ug 2 times / day multiple, oral Overdose Dose: 15000 ug, 2 times / day Route: oral Route: multiple Dose: 15000 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 30 n = 1 Health Status: unhealthy Condition: Hypothyroidism Age Group: 30 Sex: F Population Size: 1 Sources: Page: p.2 |
Nausea | Disc. AE | 15000 ug 2 times / day multiple, oral Overdose Dose: 15000 ug, 2 times / day Route: oral Route: multiple Dose: 15000 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 30 n = 1 Health Status: unhealthy Condition: Hypothyroidism Age Group: 30 Sex: F Population Size: 1 Sources: Page: p.2 |
Vomiting | Disc. AE | 15000 ug 2 times / day multiple, oral Overdose Dose: 15000 ug, 2 times / day Route: oral Route: multiple Dose: 15000 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 30 n = 1 Health Status: unhealthy Condition: Hypothyroidism Age Group: 30 Sex: F Population Size: 1 Sources: Page: p.2 |
Headache | severe Disc. AE |
15000 ug 2 times / day multiple, oral Overdose Dose: 15000 ug, 2 times / day Route: oral Route: multiple Dose: 15000 ug, 2 times / day Sources: Page: p.2 |
unhealthy, 30 n = 1 Health Status: unhealthy Condition: Hypothyroidism Age Group: 30 Sex: F Population Size: 1 Sources: Page: p.2 |
Loose stools | 100% DLT |
50 ug 2 times / day multiple, oral Highest studied dose Dose: 50 ug, 2 times / day Route: oral Route: multiple Dose: 50 ug, 2 times / day Sources: Page: p.3 |
unhealthy, 39 ± 6.2 n = 2 Health Status: unhealthy Condition: Multiple sclerosis Age Group: 39 ± 6.2 Sex: M+F Population Size: 2 Sources: Page: p.3 |
Anxiety | 50% DLT |
50 ug 2 times / day multiple, oral Highest studied dose Dose: 50 ug, 2 times / day Route: oral Route: multiple Dose: 50 ug, 2 times / day Sources: Page: p.3 |
unhealthy, 39 ± 6.2 n = 2 Health Status: unhealthy Condition: Multiple sclerosis Age Group: 39 ± 6.2 Sex: M+F Population Size: 2 Sources: Page: p.3 |
Tachycardia | 50% DLT |
50 ug 2 times / day multiple, oral Highest studied dose Dose: 50 ug, 2 times / day Route: oral Route: multiple Dose: 50 ug, 2 times / day Sources: Page: p.3 |
unhealthy, 39 ± 6.2 n = 2 Health Status: unhealthy Condition: Multiple sclerosis Age Group: 39 ± 6.2 Sex: M+F Population Size: 2 Sources: Page: p.3 |
PubMed
Title | Date | PubMed |
---|---|---|
Thyroid hormone regulation of apoptosis induced by retinoic acid in promyeloleukemic HL-60 cells: studies with retinoic acid receptor-specific and retinoid x receptor-specific ligands. | 2000 Dec |
|
Spatio-temporal expression of TSH beta and FSH beta genes in normally metamorphosing, metamorphosed, and metamorphosis-arrested Hynobius retardatus. | 2000 Sep |
|
Neurofilament expression in cultured rat adenohypophysial cells. | 2001 |
|
Hypothalamus-hypophysis-thyroid axis, triiodothyronine and antithyroid antibodies in patients with primary and secondary Sjögren's syndrome. | 2001 |
|
Influence of thyroid hormone on 5-HT(1A) and 5-HT(2A) receptor-mediated regulation of hippocampal BDNF mRNA expression. | 2001 |
|
Effect of transient early hyperthyroidism on onset of puberty in Suffolk ram lambs. | 2001 Apr |
|
Thyroid hormone increases pacemaker activity in rat neonatal atrial myocytes. | 2001 Apr |
|
Expression and regulation of osteopontin and connective tissue growth factor transcripts in rat anterior pituitary. | 2001 Apr |
|
Habituation of thermal sensations, skin temperatures, and norepinephrine in men exposed to cold air. | 2001 Apr |
|
Variable effects of goitrogens in inducing precocious metamorphosis in sea lampreys (Petromyzon marinus). | 2001 Apr 15 |
|
Nuclear cytoplasmic shuttling by thyroid hormone receptors. multiple protein interactions are required for nuclear retention. | 2001 Apr 6 |
|
Changes in serum thyroid hormone levels in newborn calves as a diagnostic index of endemic goiter. | 2001 Feb |
|
Prenatal diagnosis and early in utero management of fetal dyshormonogenetic goiter. | 2001 Feb |
|
Regulation of mucin gene expression in human tracheobronchial epithelial cells by thyroid hormone. | 2001 Feb 1 |
|
Identification of two novel splicing variants of human type II iodothyronine deiodinase mRNA. | 2001 Feb 14 |
|
Measurement of serum concentrations of free thyroxine, total thyroxine, and total triiodothyronine in cats with hyperthyroidism and cats with nonthyroidal disease. | 2001 Feb 15 |
|
Thyroid hormone activation in human vascular smooth muscle cells: expression of type II iodothyronine deiodinase. | 2001 Feb 16 |
|
Thyroid hormone: targeting the vascular smooth muscle cell. | 2001 Feb 16 |
|
Inhibition of T3 production in levothyroxine-treated female mice by the root extract of Convolvulus pluricaulis. | 2001 Jan |
|
Influence of selenium supplements on the post-traumatic alterations of the thyroid axis: a placebo-controlled trial. | 2001 Jan |
|
Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases. | 2001 Jan |
|
Endogenous depression, thyroid function and acupuncture. | 2001 Jan |
|
Influence of a high ambient temperature on lipid metabolism in the growing pig. | 2001 Jan |
|
Endocrine relationships of Meishan and White composite females after weaning and during the luteal phase of the estrous cycle. | 2001 Jan |
|
Toxic multinodular goitre in a patient with generalized resistance to thyroid hormone who harbours the R429Q mutation in the thyroid hormone receptor beta gene. | 2001 Jan |
|
Isocaloric carbohydrate deprivation induces protein catabolism despite a low T3-syndrome in healthy men. | 2001 Jan |
|
Effects of different activity and inactivity paradigms on myosin heavy chain gene expression in striated muscle. | 2001 Jan |
|
Subclinical thyrotoxicosis. | 2001 Jan |
|
Triiodothyronine-mediated up-regulation of UCP2 and UCP3 mRNA expression in human skeletal muscle without coordinated induction of mitochondrial respiratory chain genes. | 2001 Jan |
|
Structure and expression of the transthyretin gene in the choroid plexus: a model for the study of the mechanism of evolution. | 2001 Jan 1 |
|
Thyroid hormone stimulates acetyl-coA carboxylase-alpha transcription in hepatocytes by modulating the composition of nuclear receptor complexes bound to a thyroid hormone response element. | 2001 Jan 12 |
|
Thyroid hormone deficiency alters extracellular matrix protein expression in rat brain. | 2001 Jan 31 |
|
Hormone binding by protein disulfide isomerase, a high capacity hormone reservoir of the endoplasmic reticulum. | 2001 Jan 5 |
|
Role of thyroid hormones in hepatic effects of peroxisome proliferators. | 2001 Jan-Feb |
|
Androgen-Dependent transcriptional regulation of the prostate-specific antigen gene by thyroid hormone 3,5,3'-L-triiodothyronine. | 2001 Jan-Feb |
|
An array of positioned nucleosomes potentiates thyroid hormone receptor action in vivo. | 2001 Jun 8 |
|
The effects of triiodothyronine augmentation on antithrombin III levels in sepsis. | 2001 Mar |
|
Perioperative considerations in a hypothyroid infant with hepatic haemangioma. | 2001 Mar |
|
Selenium decreases thyroglobulin concentrations but does not affect the increased thyroxine-to-triiodothyronine ratio in children with congenital hypothyroidism. | 2001 Mar |
|
Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind, placebo-controlled study. | 2001 Mar |
|
Homogeneous enzyme immunoassay for triiodothyronine in serum. | 2001 Mar |
|
Distinct tissue-specific roles for thyroid hormone receptors beta and alpha1 in regulation of type 1 deiodinase expression. | 2001 Mar |
|
Hormone selectivity in thyroid hormone receptors. | 2001 Mar |
|
Thyroid hormones regulate pituitary growth hormone secretagogue receptor gene expression. | 2001 Mar |
|
Effects of prolonged fasting on plasma cortisol and TH in postweaned northern elephant seal pups. | 2001 Mar |
|
Insulin-like growth factor binding proteins in femoral and vertebral bone marrow stromal cells: expression and regulation by thyroid hormone and dexamethasone. | 2001 Mar 26 |
|
Thyroid hormone promotes serine phosphorylation of p53 by mitogen-activated protein kinase. | 2001 Mar 6 |
|
Effect of different drugs on the level of DNA-hydrolyzing polyclonal IgG antibodies in sera of patients with Hashimoto's thyroiditis and nontoxic nodal goiter. | 2001 Mar-Apr |
|
Transcriptional repression by thyroid hormone receptors. A role for receptor homodimers in the recruitment of SMRT corepressor. | 2001 May 18 |
|
Slower skeletal muscle phenotypes are critical for constitutive expression of Hsp70 in overloaded rat plantaris muscle. | 2006 Mar |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1606687
The relative affinity of the rat synaptosomes for various T3 analogs was measured by incubating [3H]T3 with increasing amounts of T3, D-T3, T4, TRIAC and rT3, The results were expressed as the molar ratio of the concentrations of T3 or analog needed to decreaseby 50% the binding of [3H]T3.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 23:03:26 UTC 2023
by
admin
on
Wed Jul 05 23:03:26 UTC 2023
|
Record UNII |
06LU7C9H1V
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 862.1715
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
||
|
LOINC |
83124-8
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
||
|
LOINC |
26879-7
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
||
|
LOINC |
83125-5
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
||
|
FDA ORPHAN DRUG |
539116
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
||
|
NCI_THESAURUS |
C1553
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
||
|
WHO-VATC |
QH03AA03
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
||
|
NDF-RT |
N0000006165
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
||
|
CFR |
21 CFR 862.1710
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
||
|
CFR |
21 CFR 520.1284
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
||
|
LOINC |
3053-6
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
||
|
LOINC |
14930-2
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
||
|
WHO-ATC |
H03AA03
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
||
|
LOINC |
3055-1
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
||
|
NDF-RT |
N0000175946
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
||
|
NCI_THESAURUS |
C886
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
||
|
LIVERTOX |
1000
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
||
|
LOINC |
70152-4
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
||
|
NDF-RT |
N0000006165
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
||
|
LOINC |
35231-0
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
||
|
LOINC |
57899-7
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
06LU7C9H1V
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
PRIMARY | |||
|
1368008
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
PRIMARY | |||
|
57164-27-9
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
SUPERSEDED | |||
|
1585
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
PRIMARY | |||
|
SUB08527MIG
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
PRIMARY | |||
|
DTXSID8023216
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
PRIMARY | |||
|
229-999-3
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
PRIMARY | |||
|
10814
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
PRIMARY | RxNorm | ||
|
100000082541
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
PRIMARY | |||
|
80203
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
PRIMARY | |||
|
DB00279
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
PRIMARY | |||
|
M6835
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
PRIMARY | Merck Index | ||
|
3110
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
PRIMARY | |||
|
C907
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
PRIMARY | |||
|
653
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
PRIMARY | |||
|
06LU7C9H1V
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
PRIMARY | |||
|
18258
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
PRIMARY | |||
|
Liothyronine
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
PRIMARY | |||
|
6893-02-3
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
PRIMARY | |||
|
LIOTHYRONINE
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
PRIMARY | |||
|
CHEMBL1544
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
PRIMARY | |||
|
2634
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
PRIMARY | |||
|
D014284
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
PRIMARY | |||
|
533015
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
PRIMARY | |||
|
7013-53-8
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
SUPERSEDED | |||
|
5920
Created by
admin on Wed Jul 05 23:03:26 UTC 2023 , Edited by admin on Wed Jul 05 23:03:26 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
RACEMATE -> ENANTIOMER | |||
|
SALT/SOLVATE -> PARENT | |||
|
LABELED -> NON-LABELED | |||
|
TRANSPORTER -> SUBSTRATE | |||
|
LABELED -> NON-LABELED | |||
|
TRANSPORTER -> SUBSTRATE | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE ACTIVE |
MAJOR
|
||
|
PRODRUG -> METABOLITE ACTIVE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
The relative response factor is 1.00
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |